ISRCTN16425757 https://doi.org/10.1186/ISRCTN16425757

Deferred registration - Klear Bio Code: KLR003-Clin-004

Submission date 24/09/2026	**Recruitment status** Recruiting	[_] Prospectively registered [_] Protocol
Registration date 01/10/2026	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 06/11/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Contact information

Type(s)
Public

Contact name
None Timothy P Reilly

Contact details
Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
United States of America
MA 02139
+1 (617) 256-2763
clinicaltrials@klear.bio

Type(s)
Scientific

Contact name
None Timothy P Reilly

Contact details
Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
United States of America

MA 02139
+1 (617) 256-2763
Tim@klear.bio

Type(s)
Principal investigator

Contact name
None Hamish Hunter

Contact details
Medicines Evaluation Unit (MEU) Ltd
The Langley Building
Southmoor Road
Manchester
United Kingdom
M23 9QZ6
+44 0161 946 4071
hhunter@meu.org.uk

Additional identifiers

Clinical Trials Information System (CTIS)
2026-525575-22-00

Integrated Research Application System (IRAS)
1014010

Central Portfolio Management System (CPMS)
76628

Sponsor code
KLR003-Clin-004

Study information

Scientific Title
Deferred registration - Klear Bio Code: KLR003-Clin-004 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 10/09/2026, North East - York Research Ethics Committee (Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; york.rec@hra.nhs.uk), ref: 26/NE/0079

Primary study design
Interventional

Allocation
Randomized controlled trial

Masking
Blinded (masking used)

Control
Placebo

Assignment
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Purpose
Treatment

Study type(s)

Health condition(s) or problem(s) studied
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Interventions
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Primary outcome(s)
1. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date measured using [Metric or method of measurement] at [Timepoint(s)]

Key secondary outcome(s)

Completion date
30/10/2028

Eligibility

Key inclusion criteria
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
18 Years

Upper age limit
65 Years

Sex
All

Total final enrolment
0

Key exclusion criteria
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Date of first enrolment
13/05/2026

Date of final enrolment
05/06/2028

Locations

Countries of recruitment
United Kingdom

England

Netherlands

United States of America

Study participating centre
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
-
England
-

Sponsor information

Organisation
Klear Bio, Inc.

Funder(s)

Funder type

Funder Name
Klear Bio, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available